Опыт применения препарата маннитол (Бронхитол-Фармаксис) у пациентов детского возраста с муковисцидозом в Московском регионе
Victoria Davidovna Sherman, Anna Y. Voronkova, Е. И. Кондратьева et al. · Пульмонология · 2019
The objective of this study was to assess clinical efficacy and safety of inhaled mannitol (Bronchitol-Pharmaxis) in cystic fibrosis (CF) children at Moscow region. Methods. The study was designed as a single centre, observational study. Inclusion criteria were age > 9 years, confirmed diagnosis of CF and tolerability of mannitol in the BIDA test (Bronchitol Inhaled Dose Assessment). Mannitol was administered in the dose of 400 mg (10 capsules, 40 mg each) b.i.d. after inhalation of a short-acting bronchodilator. The patients also received basic therapy excluding inhaled hypertonic saline. The treatment duration was 8 weeks. Patients visited a physician at the study beginning and over 8 weeks of treatment; lung function (FEV1, FVC) and blood oxygen saturation (SatO2) were measured at each visit. Results. Lung function was stable or tended to improvement during the study. Time spent to inhalations of mannitol shortened compared to previous treatment with inhaled mucolytics and hypertonic saline. Inhaled mannitol was well-tolerated. Conclusion. The study demonstrated good tolerability and clinical efficacy of inhaled mannitol in CF children. Dry-powder formulation is also beneficial due to shorter time required for inhalation.
Cited by 2 works. doi:10.18093/0869-0189-2019-29-4-436-442